IL2RA and neoplasm: Despite a small proportion loss of CD4+ T cells by anti-CD25 mAbs in the combination treatment group, there were significantly more infiltrating CD8+ T cells and CD11c+ DCs into the tumor (P < 0.01, Figure 6B), especially marked induction of tumor-specific CD8+ cytotoxic T lymphocytes (CTLs) at the local tumor site (Figure 6A).